- Cassava Sciences ( NASDAQ: SAVA ) closed up ~10% Wednesday as the biotech indicated it may have open-label study data on its Alzheimer's candidate simufilam ready by the end of the year .
- The company said it has completed drug administration in the trial of 200 patients with mild-to-moderate Alzheimer's.
- Participants are given simufilam 100mg twice daily over 12 months.
- Cassava ( SAVA ) is now awaiting analysis of the data by independent biostatisticians.
- Separately, there are two ongoing, placebo-controlled phase 3 trials of simufilam, RETHINK-ALZ and REFOCUS-ALZ. The former is examining the drug's impact of 52 week, while the latter, 76 weeks.
For further details see:
Why did Cassava Sciences stock jump today? Possible Alzheimer's data soon